Background: The administration of the coronavirus disease 2019 (COVID-19) vaccine aims to stimulate the production of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies. This leads to an enhanced production of neutralizing antibodies (Nabs), which naturally neutralize the virus within the body, thereby reducing the risk of COVID-19 infection. This study determined the analysis of factors affecting SARS-CoV-2 antibody levels in vaccinated individuals using data from the COVID-19 Seroepidemiological Survey of Gowa Regency.
Methods And Material: This was an with a design. The COVID-19 Seroepidemiology Survey data as a whole were 851 individuals, and in this study, the number of samples was 804 individuals from all COVID-19 Seroepidemiology Survey samples who had performed the COVID-19 vaccine in Gowa Regency, selected through .
Statistical Analysis Used: Data analysis was conducted using various statistical tests, including the independent-samples -test, Mann-Whitney test, Kruskal-Wallis test, and multiple logistic regression. Furthermore, the analysis was performed through the STATA program version 14.0.
Results: There was a significant influence between the history of COVID-19 infection ( = 0.0006) and dose of vaccine ( = 0.0001) with SARS-CoV-2 antibody levels in vaccinated individuals. Meanwhile, vitamin consumption and comorbid history did not affect SARS-CoV-2 antibody levels. Multivariate analysis showed that vaccine dose was the most influential variable on antibody levels ( = 0.046; Odds Ratio (OR) 0.19; 95% Confidence Interval (CI): 0.036-0.968).
Conclusions: The most influential factor was the vaccine dose on SARS-CoV-2 antibody levels in community in Gowa Regency.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10977628 | PMC |
| http://dx.doi.org/10.4103/jehp.jehp_886_23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Replication-incompetent VSV-based vaccine elicits protective responses against SARS-CoV-2 and influenza virus.
Sci Adv
January 2025
Department of Microbiology and Immunology, Cornell University College of Veterinary Medicine, Ithaca, NY 14853, USA.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses lead to severe respiratory illnesses and death in humans, exacerbated in individuals with underlying health conditions, remaining substantial global public health concerns. Here, we developed a bivalent replication-incompetent single-cycle pseudotyped vesicular stomatitis virus vaccine that incorporates both a prefusion-stabilized SARS-CoV-2 spike protein lacking a furin cleavage site and a full-length influenza A virus neuraminidase protein. Vaccination of K18-hACE2 or C57BL/6J mouse models generated durable levels of neutralizing antibodies, T cell responses, and protection from morbidity and mortality upon challenge with either virus.
View Article and Find Full Text PDFScrub typhus association with autoimmune biomarkers and clinical implications.
PLoS Negl Trop Dis
January 2025
Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Republic of Korea.
Background: Scrub typhus, a disease caused by Orientia tsutsugamushi, triggers systemic vasculitis and is prevalent in Eastern and Southern Asia. This study aimed to uncover the relationship between scrub typhus and autoimmune responses, focusing on antinuclear antibodies (ANAs) and the implications of elevated ANA titers during infection.
Method: Data from a total of 139 patients diagnosed with scrub typhus and 30 healthy controls were retrospectively analyzed through serum samples to assess the levels of ANAs and related autoantibodies.
Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer.
Eur J Nucl Med Mol Imaging
January 2025
Departments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, WI, 53705, USA.
Purpose: Trophoblast cell-surface antigen 2 (Trop2) is overexpressed in various solid tumors and contributes to tumor progression, while its expression remains low in normal tissues. Trop2-targeting antibody-drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), has shown efficacy in targeting this antigen. Leveraging the enhanced specificity of ADCs, we conducted the first immunoPET imaging study of Trop2 expression in gastric cancer (GC) and triple-negative breast cancer (TNBC) models using Zr-labeled Trodelvy ([Zr]Zr-DFO-Trodelvy).
View Article and Find Full Text PDFDevelopment of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography.
Eur J Nucl Med Mol Imaging
January 2025
Institute of Radiation Medicine, Fudan University, Xietu Road 2094, Shanghai, 200032, China.
Objectives: Mesothelin (MSLN) is an antigen that is overexpressed in various cancers, and its interaction with tumor-associated cancer antigen 125 plays a multifaceted role in tumor metastasis. The serum MSLN expression level can be detected using enzyme-linked immunosorbent assay; however, non-invasive visualization of its expression at the tumor site is currently lacking. Therefore, the aim of this study was to develop a molecular probe for imaging MSLN expression through positron emission tomography (PET).
View Article and Find Full Text PDFBiologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
COPD
December 2025
Division of Respirology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Background: Despite limited breakthroughs in COPD pharmacotherapy, recent trials have shown promising results for biologics in COPD patients. However, robust evidence synthesis in this area is currently lacking.
Methods: We conducted a systematic review of MEDLINE, EMBASE, and Cochrane CENTRAL from inception to July 17, 2024, to identify randomized trials of biologic medications in patients with COPD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!